hrs-5041
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2023 (NCT05942001)
Timeline
Indications
Mechanism of action
- Androgen ReceptorDEGRADER
AR degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07115446 | Phase 1 | Aug 31, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT07014488 | Phase 1 | Jun 20, 2025 | Hengrui Therapeutics, Inc. |
| NCT06830850 | Phase 1 | Jun 15, 2025 | Atridia Pty Ltd. |
| NCT06738745 | Phase 2 | Dec 31, 2024 | Fudan University |
| NCT06559007 | Phase 1 | Sep 25, 2024 | Atridia Pty Ltd. |
| NCT06568094 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2024 | Hengrui Therapeutics, Inc. |
| NCT05942001 | Phase 1 | Sep 15, 2023 | Hengrui Therapeutics, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2023 |
| Atridia Pty Ltd. | For profit | 2 | 2 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1